Just in recent memory, investors have had little problem with talking highly-valued med-tech stories like Edwards Lifesciences (EW), Intuitive Surgical (ISRG), and Cepheid (CPHD) and pushing them even higher on their uncommonly strong revenue growth numbers. Along those same lines, I think HeartWare (HTWR)
could continue to head higher, despite an already rich valuation, on
news of strong share/unit growth. That said, investors would do well to
notice that the three aforementioned stocks have all had periods where
the stock sold off pretty sharply (and pretty quickly), so HeartWare is
not for the faint of heart.
Read more here:
HeartWare Is Premium-Priced Growth, But Could Still Go Higher
No comments:
Post a Comment